Clinical Trial

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata

Study acronym: THRIVE-AAJP
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-03
notable Trial sites expanded: 0 -> 18 locations 2026-07-03
Trial Details
NCT Number NCT07617597
Lead Sponsor Sun Pharma Japan Limited
Conditions Alopecia Areata
Enrollment 78 participants
Start Date 2026-06-19
Primary Completion 2028-02 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-20